Categories Health Care, IPO

IPO news: Cingulate is making its market debut this week, here’s what to know

The company will offer 4.6 million shares at a price range of $10 to $12 to raise $50.1 million

The biopharmaceuticals market was valued at approx. $325.17 billion in 2020 and it is expected to grow at a CAGR of 7.3% over the next five years, based on data from Mordor Intelligence. There is always a huge demand for medicines that are easier to administer and that are less expensive. One such company that is working on addressing these issues is Cingulate Inc. and this biopharma company is set to make its market debut this week.

IPO details

Cingulate Inc. is slated to go public on Thursday, October 7. The company will begin trading on NASDAQ under the ticker symbol CING. It will offer 4.6 million shares at a price range of $10 to $12 to raise $50.1 million. The IPO will be managed by a group of underwriters led by Oppenheimer & Co.

Company intro

Cingulate is a clinical stage biopharmaceutical company focused on developing medicines that can help patients suffering from medical conditions with burdensome daily dosing regimens. The company’s initial efforts are focused on the treatment of Attention Deficit/Hyperactivity Disorder or ADHD.

Stimulants are the most commonly prescribed class of medications for ADHD, comprising 90% of all medication prescriptions for this condition in the US. Cingulate’s two proprietary first-line stimulant medications, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD in children, adolescents and adults.

The company’s products are designed to take effect immediately, last for an entire day, eliminate the need for a booster dose, and reduce or eliminate rebound/crash symptoms. Cingulate plans to start Phase 3 trials for CTx-1301 in the fourth quarter of 2021 with results expected in late 2022, and a Phase 1/2 bioavailability study for CTx-1302 in early 2022.


Cingulate has not begun generating revenue from its products. In 2020, the company incurred a net loss of $7.1 million compared to a loss of $11.5 million in 2019. For the first six months of 2021, Cingulate posted a net loss of $2.7 million versus a loss of $4.8 million in the same period a year ago.

Market opportunity

In the US, approx. 6.4 million, or 11% of children and adolescents aged 4-17 have been diagnosed with ADHD. Of this, 80% receive treatment and 65% show clinical ADHD symptoms that persist into adulthood. Adult ADHD prevalence in the US is estimated at approx. 4.4% of the population.

The adult ADHD market is growing approx. 10% year-over-year. Total ADHD medication sales in the US have grown approx. 8% each year since 2010 with sales of all ADHD medications reaching around $18.3 billion in 2020.

Click here to read more IPO-related stories

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Seagate Technology beats Q1 earnings estimate: Infographic

Seagate Technology (NYSE: ALK) reported first-quarter 2022 financial results before the regular market hours on Friday. The company reported Q1 revenue of $3.12 billion, up 35% year-over-year and higher than

Infographic: Schlumberger (SLB) Q3 2021 Earnings Results

Schlumberger Limited (NYSE: SLB) came up with its third-quarter 2021 results on Friday. Revenue increased to $5.8 billion from $5.2 billion last year. Analysts had expected revenue of $5.09 billion.

Honeywell (HON) Q3 2021 Earnings: Key financials and quarterly highlights

Honeywell International Inc. (NASDAQ: HON) reported third quarter 2021 earnings results today. Sales increased 9% year-over-year to $8.4 billion but missed projections of $8.6 billion. On an organic basis, sales

Add Comment
Viewing Highlight